

Structural insight into antibiotic-inactivating enzyme from *Stenotrophomonas maltophilia*

Stenotrophomonas maltophilia is an opportunistic bacterial pathogen responsible for a serious number of infections globally. It exhibits broad antibiotic resistance that has been further extended via the acquisition of antibiotic-resistance genes and mutations [1]. We carried out a bioinformatic analysis of its sequenced genomes to investigate not yet characterised antibiotic-inactivating enzymes.

Several chosen proteins were expressed in *Escherichia coli* strain Lemo21 (DE3) and purified using Ni-NTA and size-exclusion chromatography. Their proposed function – enzymatic modification of antibiotics – was inspected with an activity assay. The enzyme with the confirmed activity was successfully crystallized and diffraction patterns were collected. The data exhibited serious anisotropy: a resolution cutoff determined in Aimless [2], according to the criterion of $CC1/2 \leq 0.30$, varied from 2.43 Å to 1.92 Å in different reciprocal space directions. Thus, the data were corrected with STARANISO [3]. After the solution of the phase problem in MoRDa [4], the model was refined in REFMAC5 [5]. The choice of the anisotropic high-resolution diffraction limit (1.88 Å) was confirmed with paired refinement in PAIRREF [6].

The solved X-ray crystal structure reveals an atomic arrangement of the putative substrate-binding pocket that allows further structural analysis (in silico or in vitro) of complexes with potential inhibitors or antibiotic substrates. The overall fold is very close to the tetracycline destructases [7] or the reductase involved in the abyssomicin biosynthesis pathway [8]. However, the putative active site differs significantly. Our study leads to a better understanding of the involvement of this enzyme in the antibiotic resistance and could contribute to the development of new strategies of antibiotic therapies. Remarkably, the solved structure is composed of a homodimer linked with two disulfides. Nevertheless, further investigation using small-angle X-ray scattering, mass spectrometry and dynamic light scattering showed that the protein is monomer in solution.

1. T. Gil-Gil, J. L. Martínez, P. Blanco, Expert Review of Anti-infective Therapy, 18, (2020), pp. 335-347.
2. P. R. Evans, G. N. Murshudov, Acta Cryst., D69, (2013), pp. 1204-1214.
3. I. J. Tickle, C. Flensburg, P. Keller, W. Paciorek, A. Sharff, C. Vonrhein, G. Bricogne. (2018). STARANISO (<http://staraniso.globalphasing.org/cgi-bin/staraniso.cgi>). Cambridge, United Kingdom: Global Phasing Ltd.
4. A. Vagin, A. Lebedev, Acta Cryst., A71, (2015), s19.
5. G. N. Murshudov, P. Skubak, A. A. Lebedev, N. S. Pannu, R. A. Steiner, R. A. Nicholls, M. D. Winn, F. Long, A. A. Vagin, Acta Cryst., D67, (2011), pp. 355-367.
6. M. Malý, K. Diederichs, J. Dohnálek, P. Kolenko, IUCrJ, 7, (2020), 681-692.
7. J. L. Markley, T. A. Wencewicz, Frontiers in microbiology, 9, (2018), 1058.
8. J. A. Clinger, X. Wang, W. Cai, Y. Zhu, M. D. Miller, C. G. Zhan, S. G. Van Lanen, J. S. Thorson, G. N. Phillips Jr., Proteins. 89, (2021), pp. 132-137.

Primary authors: MALÝ, Martin (CTU FNSPE); KOLENKO, Petr (CTU FNSPE); DOHNÁLEK, Jan (Institute of Biotechnology AS CR, v.v.i.)